Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Phase 1
Completed
- Conditions
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaT-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Transformed Mycosis FungoidesRecurrent Transformed Mycosis FungoidesRecurrent Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Walter Hanel
- Target Recruit Count
- 5
- Registration Number
- NCT04774068
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath